1. Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma.
- Author
-
Mylam, Karen J., El-Galaly, Tarec C., Hutchings, Martin, Brown, Peter, Himmelstrup, Bodil, Gerke, Oke, Gillstrøm, Dorte, Sillesen, Ida B., Munksgaard, Lars, Pedersen, Bjarne B., Christiansen, Ilse, Jensen, Paw, Nielsen, Anne L., and Pedersen, Lars M.
- Subjects
LYMPHOMAS ,PROGNOSIS ,POSITRON emission tomography ,COMPUTED tomography ,B cell lymphoma ,DIAGNOSTIC imaging ,IMAGE analysis ,PROGRESSION-free survival ,PATIENTS - Abstract
The aim of this study was to evaluate the prognostic value of clinician interpretation of positron emission tomography/computed tomography (PET/CT) reports at mid-therapy, interim PET (I-PET) and after the end of first-line therapy (E-PET) in patients with diffuse large B-cell lymphoma (DLBCL). Four hundred and thirty patients were enrolled in this study comprising a total of 617 PET reports. Each report was evaluated by three expert hematologists randomly selected from a panel of nine. Reports were labeled positive or negative if all three interpreters agreed. All others were considered indeterminate. Indeterminate reports accounted for 59% of I-PET and 49% of E-PET reports. Two-year overall survival (OS) for patients with a positive, indeterminate and negative I-PET was 58%, 87% and 89% ( p < 0.001), respectively. Two-year OS for patients with E-PET was 41%, 89% and 97% ( p < 0.001) for positive, indeterminate and negative interpretation of PET/CT reports. Progression-free survival and OS did not differ significantly in patients with a negative and an indeterminate I-PET report. The use of well-defined reporting criteria, e.g. the Deauville five-point scale, is likely to reduce the number of scans perceived as indeterminate. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF